Skip to main content
Log in

Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder characterized predominantly by recurrent orogenital ulcers, skin involvement, and uveitis. Recurrent mucocutaneous lesions may be the only symptom in mild cases, but ocular, gastrointestinal, and central nervous system involvement may occur in severe cases. We report in this study the successful treatment with infliximab of severe life-threatening GI bleeding caused by an ileal ulcer in a patient with Behçet’s disease. Antitumor necrosis factor (TNF) therapy could be an emergency therapeutic option in patients with massively bleeding Behçet’s disease and unstable patients or those with acute bleeding with other TNF-α-mediated autoimmune diseases. Another option for anti-TNF therapy could be as bridging management between conservative and surgical treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. International study group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  2. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T (1981) Intestinal involvement in Behçet’s disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 24:103–106

    Article  PubMed  CAS  Google Scholar 

  3. Haugeberg G, Velken M, Johnsen V (2004) Successful treatment of genital ulcers with infliximab in Behçet’s disease. Ann Rheum Dis 63:744–745

    Article  PubMed  CAS  Google Scholar 

  4. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120:995–999

    Article  PubMed  CAS  Google Scholar 

  5. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296

    Article  PubMed  CAS  Google Scholar 

  6. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL (2001) Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725–728

    Article  PubMed  CAS  Google Scholar 

  7. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096

    Article  PubMed  CAS  Google Scholar 

  8. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89:533–536

    Article  PubMed  CAS  Google Scholar 

  9. Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K (2003) Successful treatment of cervical esophageal perforation in Behçet’s disease with drainage operation and infliximab. Am J Gastroenterol 98:703–704

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sung-Hwan Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ju, J.H., Kwok, SK., Seo, SH. et al. Successful treatment of life-threatening intestinal ulcer in Behçet’s disease with infliximab: rapid healing of Behçet’s ulcer with infliximab. Clin Rheumatol 26, 1383–1385 (2007). https://doi.org/10.1007/s10067-006-0410-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0410-3

Keywords

Navigation